Form 4: Alnylam Pharmaceuticals Executive Tolga Tanguler Reports Stock Transactions

Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, reports the acquisition of restricted stock units and the sale of common stock to cover tax obligations.

Summary

• On March 3, 2025, Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, engaged in transactions involving the company's stock.
• Tanguler acquired 14,137 restricted stock units (RSUs) under the company's 2018 Stock Incentive Plan, each representing a contingent right to receive one share of common stock.
• These RSUs vest over a three-year period, with one-third vesting annually, contingent upon continuous service with the issuer.
• Tanguler also sold shares of common stock to cover minimum statutory tax withholding obligations due upon the vesting and settlement of RSUs.
• The sales were executed in multiple transactions at prices ranging from $241.87 to $247.52.
• Following these transactions, Tanguler directly owns 28,011 shares of common stock.
• Tanguler also holds 7,819 stock options with an exercise price of $243.53, vesting over four years from the grant date, and 1,666 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. The sale of shares is for tax obligations, which is a normal occurrence.

Positives

• The acquisition of RSUs indicates a continued alignment of the executive's interests with the company's long-term performance.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it is a common practice.

Risks

• The vesting of RSUs and stock options is contingent upon continued service with the company, creating a potential risk if the executive were to leave.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's prospects. Form 4 filings are a standard part of regulatory compliance.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, and restricted stock units to incentivize performance and align interests with shareholders.
• The vesting schedules for RSUs and stock options are typical, often spanning three to four years with annual or quarterly vesting increments.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates

Keywords

Alnylam Pharmaceuticals, Tolga Tanguler, stock transactions, restricted stock units, RSUs, stock options, Form 4, insider trading